Figure 1 Patient selection flow chart

Slides:

Advertisements

Similar presentations

Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.

Advertisements

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.

Figure 1 Periprocedural myonecrosis and myocardial infarction after left main coronary artery revascularization with ... Figure 1 Periprocedural myonecrosis.

Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes.

Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 Overall lag-cumulative exposure–response relationships between air temperature and myocardial infarction ... Figure 1 Overall lag-cumulative exposure–response.

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 Data-selection process

Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Multivariable-adjusted predictors of PAC

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.

Figure 1 Mechanism of mortality benefit associated with radial access

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.

Figure 1. Multivariable-adjusted hazard ratios (solid line) for incident chronic obstructive pulmonary disease as a ... Figure 1. Multivariable-adjusted.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 Sources of uncertainty introduced in each stage of the standard modelling approach for estimating ... Figure 1 Sources of uncertainty introduced.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

bDMARD: biologic DMARD.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

RCTs: randomized controlled ...

Take home figure The protective role of CNP/NPR-B/NPRC.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

x-axis, post-partum days. Closed ...

Take home figure The 38% of heart failure reduced ejection fraction (HFrEF) patients who recovered LVEF (HFrecEF) were more ... Take home figure The 38%

Figure 1 Representative examples of three-dimensional volume-rendered CT images of AOLCA (A) and AORCA (B) with an IAC ... Figure 1 Representative examples.

Fig. 1 Subacute cutaneous lupus erythematous at the lower limbs

Fig. 1 Flow chart of included patients for analyses

Fig. 1 Flow chart for selection of study subjects

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Selection algorithm of patients being included in the German Aortic Valve Registry in 2014 and Figure 1 Selection algorithm of patients.

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Relationships between pair indices of dance performance (joint entropy or mutual information) and the past ... Figure 1 Relationships between.

Figure 1. The derivation of the cohort.

Figure 1 Study flowchart and patient flow

Figure 1 Immunohistochemistry for human cell differentiation molecules in samples of the right ventricular septum from ... Figure 1 Immunohistochemistry.

Figure 1. Percentage of Pacific and European children completing all components of B4SC in 2013 and 2015 Figure 1. Percentage of Pacific and European.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure Ranking of Cardiovascular Journals as published by Clarivate Analytics. Unless provided in the caption above, the following copyright applies.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Take home figure Proposed mechanisms of Staphylococcus aureus endocarditis. CVC, central venous catheter; IV, intravenous; S. ... Take home figure Proposed.

Figure 1. Ratios of simulated hazard rates of reporting for states with high trade exposure to those with low exposure, ... Figure 1. Ratios of simulated.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 Patient selection

Figure 1 Patient disposition

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Weight loss for participants (n = 128) who consumed the high-egg (n = 66) or the low-egg (n = 62) diets ... FIGURE 1 Weight loss for participants.

FIGURE 1 Study population. EVD, Ebola virus disease.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Patient selection.

The figure shows the fraction of ...

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Mechanisms of mitral regurgitation.

(A) Amnion membrane. (B) Digital ulcers post-cleaning. (C) ...

Figure 1. Kaplan Meier curves showing crude product limit survival estimates and 95% confidence intervals for time to ... Figure 1. Kaplan Meier curves.

Figure 1 ABCDE of primary prevention.2

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Figure 1. Evolutionary process of a policy field.

Figure 1. Estimated weight functions (dotted-dashed lines) and pointwise 95% bootstrap confidence intervals (shaded ... Figure 1. Estimated weight functions.

Presentation transcript:

Figure 1 Patient selection flow chart Figure 1 Patient selection flow chart. The flow chart shows the selection of new allopurinol (or febuxostat) exposure ... Figure 1 Patient selection flow chart. The flow chart shows the selection of new allopurinol (or febuxostat) exposure episodes after applying all the eligibility criteria including the absence of any allopurinol or febuxostat filled prescription in the baseline period of 365 days (new user design) and an absence of atrial fibrillation. We found 25 732 new allopurinol or febuxostat exposure episodes in 23 135 patients. Of these, 3603 ended in incident atrial fibrillation and 22 129 ended without incident atrial fibrillation. We followed each eligible patient with a new filled allopurinol (or febuxostat) prescription until the patient lost full Medicare coverage, had atrial fibrillation (the outcome of interest), died or reached the each of the study period on 31 December 2012, whichever came first. For some of these patients the atrial fibrillation occurred on days covered by allopurinol exposure (n = 2140), febuxostat exposure (n = 171), yet other patients had periods of no allopurinol or febuxostat use after an initial qualifying prescription during which atrial fibrillation occurred (n = 1292). Every episode of allopurinol exposure, febuxostat exposure, or non-use of either drug could end with or without the occurrence of atrial fibrillation. Nb, number of beneficiaries; NE, number of qualified episodes of new allopurinol or febuxostat prescriptions; Np, number of allopurinol or febuxostat prescriptions; T<sub>E,</sub> treatment episodes. Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the European Society of Cardiology 2019. This work is written by US Government employees and is in the public domain in the US.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) Eur Heart J, ehz154, https://doi.org/10.1093/eurheartj/ehz154 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 2 Propensity-matched analyses: the association of febuxostat use with incident atrial fibrillation with ... Figure 2 Propensity-matched analyses: the association of febuxostat use with incident atrial fibrillation with allopurinol use as the reference (A), and of various durations of use of allopurinol or febuxostat and allopurinol with incident atrial fibrillation, with 1–180 day allopurinol exposure as the reference category (B), represented by hazard ratios. (A) Febuxostat use (allopurinol, reference) was associated with significantly higher hazard ratio of incident atrial fibrillation than allopurinol (reference category) in the main model (solid blue bar) and the sensitivity analyses that was limited to patients with gout (hashed bar) is shown. The error bars show the upper and lower 95% confidence intervals and neither crossed hazard ratio of 1, indicating that both were statistically significant in propensity-matched analyses. (B) Febuxostat use for 1–180 days was associated with significantly higher adjusted hazard ratio compared with allopurinol use 1–180 days (reference category represented by first solid blue bar with dots without any error bars) is shown. Longer allopurinol and longer febuxostat use durations were not significantly associated with the risk of incident AF compared with allopurinol 1–180 days. The error bars show the upper and lower 95% confidence intervals. For both A and B, the Y-axis shows hazard ratio of incident atrial fibrillation and the horizontal dotted line crossing 1 on the Y-axis represents null hypothesis. AF, atrial fibrillation; Ref, reference category. Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the European Society of Cardiology 2019. This work is written by US Government employees and is in the public domain in the US.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) Eur Heart J, ehz154, https://doi.org/10.1093/eurheartj/ehz154 The content of this slide may be subject to copyright: please see the slide notes for details.